Pelago bioscience ab

Pelago Bioscience AB: Revolutionizing Drug Discovery with CETSA® Technology

Pelago Bioscience AB is a specialized Contract Research Organization (CRO) that has been at the forefront of drug discovery for over a decade. The company's patented Cellular Thermal Shift Assay (CETSA®) technology has revolutionized the way researchers identify and validate drug targets, enabling them to develop more effective therapies for a wide range of diseases.

Founded in 2010 by Dr. Michael Dabrowski and Dr. Mikael Kubista, Pelago Bioscience AB is headquartered in Solna, Sweden, with offices in Boston, USA. The company's team of experienced scientists and technicians work closely with pharmaceutical companies, biotech firms, and academic institutions to provide bespoke projects tailored to their specific needs.

What sets Pelago Bioscience apart from other CROs is its unique CETSA® technology. This innovative approach allows researchers to measure the binding affinity between proteins and small molecules directly within cells or tissues under physiological conditions. By doing so, they can identify potential drug targets that are relevant to disease states while minimizing false positives.

The CETSA® technology works by exposing cells or tissues to increasing temperatures while monitoring changes in protein stability using mass spectrometry-based proteomics analysis. This enables researchers to determine which proteins bind specifically to small molecules at physiologically relevant concentrations.

Pelago Bioscience offers a wide range of services based on its CETSA® technology platform including target engagement studies, hit identification and validation studies as well as lead optimization studies among others. These services have been used successfully across multiple therapeutic areas such as oncology, inflammation & immunology among others.

One key advantage of working with Pelago Bioscience is its ability to provide bespoke projects tailored specifically for each client's needs rather than offering standardized packages like many other CROs do. This ensures that clients receive personalized attention from the company's team of experts, who work closely with them to design and execute experiments that meet their specific requirements.

Pelago Bioscience has a proven track record of success in drug discovery. Its CETSA® technology has been used to identify novel drug targets for a wide range of diseases, including cancer, Alzheimer's disease, and diabetes. The company has also collaborated with leading pharmaceutical companies such as AstraZeneca, Pfizer and Merck among others.

In addition to its CETSA® technology platform services, Pelago Bioscience also offers training courses on the use of the CETSA® technology for researchers interested in learning more about this innovative approach. These courses are designed to provide hands-on experience with the technology and enable researchers to apply it effectively in their own research projects.

Overall, Pelago Bioscience AB is a leading CRO that is revolutionizing drug discovery through its patented CETSA® technology platform. With its team of experienced scientists and technicians working closely with clients to provide bespoke projects tailored specifically for their needs, Pelago Bioscience is well-positioned to continue driving innovation in this field for years to come.